These findings show that inhibiting the abnormally upregulated TGF‐β pathway will only restore iWAT expansion and ameliorate the global metabolic malfunction of glucose and lipids in lipodystrophy, not obesity. The gene discussed is TGFB1; the disease is lipodystrophy.